Theriva Biologics(TOVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TOVX Theriva Biologics

交易中 06-12 14:27:08 EDT

0.3024

-0.0126

-4.00%

最高0.3144	最低0.2800	成交量688.63万
今开0.2844	昨收0.3150	日振幅10.92%
总市值1,388万	流通市值1,365万	总股本4,589万
成交额206.78万	换手率15.25%	流通股本4,514万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TOVX","market":"US","secType":"STK","nameCN":"Theriva Biologics","latestPrice":0.3024,"timestamp":1781288815852,"preClose":0.315,"halted":0,"volume":6886321,"delay":0,"changeRate":-0.04,"floatShares":45143400,"shares":45892668,"eps":-2.554,"marketStatus":"交易中","change":-0.0126,"latestTime":"06-12 14:27:08 EDT","open":0.2844,"high":0.3144,"low":0.28,"amount":2067830.4609792698,"amplitude":0.109206,"askPrice":0.3049,"askSize":1,"bidPrice":0.2985,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.554,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781294400000},"marketStatusCode":2,"adr":0,"exchange":"AMEX","adjPreClose":0.315,"preHourTrading":{"tag":"盘前","latestPrice":0.278,"preClose":0.315,"latestTime":"09:29 EDT","volume":958374,"amount":263277.4133124,"timestamp":1781270998686,"change":-0.037,"changeRate":-0.11746,"amplitude":0.119683},"postHourTrading":{"tag":"盘后","latestPrice":0.28,"preClose":0.307,"latestTime":"19:59 EDT","volume":4441116,"amount":1329789.867222,"timestamp":1781222397044,"change":-0.027,"changeRate":-0.087948,"amplitude":0.285668},"volumeRatio":0.152214},"requestUrl":"/m/hq/s/TOVX","defaultTab":"news","newsList":[{"id":"1176611075","title":"Theriva Biologics：VCN-01联合度伐利尤单抗在难治性头颈鳞癌患者中观察到总生存期延长","url":"https://stock-news.laohu8.com/highlight/detail?id=1176611075","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176611075?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:04","pubTimestamp":1781179449,"startTime":"0","endTime":"0","summary":"Theriva Biologics公司宣布，其候选药物VCN-01与度伐利尤单抗联合疗法，在治疗难治性头颈部鳞状细胞癌患者的一项研究中，观察到了总生存期的显著延长。这一积极数据为针对这一侵袭性癌症开发新的治疗选择带来了希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180471754","title":"Theriva™ Biologics 公布Vcn-01治疗头颈癌一期临床试验结果 发表于《临床癌症研究》","url":"https://stock-news.laohu8.com/highlight/detail?id=1180471754","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180471754?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:03","pubTimestamp":1781179410,"startTime":"0","endTime":"0","summary":"Theriva™ Biologics宣布，其候选疗法Vcn-01在头颈癌患者中进行的一期临床试验结果已正式发表于权威医学期刊《临床癌症研究》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179075136","title":"Theriva™ Biologics 将在AACR 2026年会上公布Vcn-01治疗转移性胰腺癌Virage二期B临床试验的补充数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1179075136","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179075136?lang=zh_cn&edition=full","pubTime":"2026-04-18 04:06","pubTimestamp":1776456374,"startTime":"0","endTime":"0","summary":"Theriva™ Biologics 宣布，即将在美国癌症研究协会（AACR）2026年年会上展示其候选药物Vcn-01针对转移性胰腺癌的Virage二期B临床试验的额外数据。该演示将提供关于Vcn-01疗效与安全性的最新分析结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120477634","title":"Theriva™ Biologics 就Vcn-01治疗转移性胰腺导管腺癌的三期试验设计与美国FDA完成积极二期结束会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120477634","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120477634?lang=zh_cn&edition=full","pubTime":"2026-03-23 20:03","pubTimestamp":1774267401,"startTime":"0","endTime":"0","summary":"Theriva™ Biologics 宣布，已成功与美国食品药品监督管理局（FDA）就其在研药物Vcn-01用于治疗转移性胰腺导管腺癌的三期临床试验设计，完成了二期结束会议，并获得了积极的反馈。\n此次会议的积极结果为推进Vcn-01的关键性三期临床试验奠定了坚实基础，标志着该疗法在针对这一难治性癌症的研发进程中迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120865995","title":"Theriva Biologics Inc：签署协议即获30万美元首付款，并有资格获得高达3800万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1120865995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120865995?lang=zh_cn&edition=full","pubTime":"2026-02-18 21:05","pubTimestamp":1771419911,"startTime":"0","endTime":"0","summary":"Theriva Biologics Inc（简称Theriva Biologics）在协议签署之际，已成功收到一笔30万美元的预付款项。此次合作还为其开启了获得后续资金的大门——该公司有资格根据协议条款，获得总额最高可达3800万美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167515399","title":"Theriva™ Biologics 将公布VCN-01视网膜母细胞瘤一期临床试验数据于2026年亚太眼科学会","url":"https://stock-news.laohu8.com/highlight/detail?id=1167515399","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167515399?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:02","pubTimestamp":1770123771,"startTime":"0","endTime":"0","summary":"Theriva™ Biologics (TOVX) 宣布，其针对视网膜母细胞瘤的VCN-01一期临床试验数据，将于2026年亚太眼科学会(Apao)上进行展示。这一重要进展标志着公司在肿瘤治疗领域的深入研究取得新突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605410082","title":"Theriva Biologics, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605410082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605410082?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:50","pubTimestamp":1769097054,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时50分，Theriva Biologics, Inc.股票出现波动，股价急速拉升5.00%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为1.00%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新型溶瘤腺病毒平台，以解决高度未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122235054a44a904e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122235054a44a904e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601286587","title":"Theriva Biologics, Inc.股价重挫11.09% 市值跌11.68万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601286587","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601286587?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:50","pubTimestamp":1767624654,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日22时50分，Theriva Biologics, Inc.股票出现波动，股价快速跳水11.09%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Gh Research Plc、Altimmune, Inc.涨幅较大，Can Fite Biopharma Ltd、Psyence Biomedical Ltd.、Outlook Therapeutics, Inc.较为活跃，换手率分别为1272.20%、19.61%、17.63%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Jasper Therapeutics Inc C/Wts 24/09/2026 、Newcelx Ltd.，振幅分别为62.64%、27.42%、27.37%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新型溶瘤腺病毒平台，以解决高度未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105225054a6f66fa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105225054a6f66fa1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145679596","title":"Theriva™ Biologics获欧洲药品管理局（EMA）关于VCN-01治疗转移性胰腺导管腺癌（PDAC）三期临床试验设计的积极科学建议","url":"https://stock-news.laohu8.com/highlight/detail?id=1145679596","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145679596?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:02","pubTimestamp":1767013333,"startTime":"0","endTime":"0","summary":"Theriva™ Biologics公司宣布，已获得欧洲药品管理局（EMA）就其候选药物VCN-01用于治疗转移性胰腺导管腺癌（PDAC）的三期临床试验设计所提出的积极科学建议。这一进展标志着VCN-01在临床开发道路上迈出了关键一步，为后续试验的顺利开展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518828739","title":"Theriva Biologics, Inc.2024财年实现净利润-25.65百万美元，同比减少39.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518828739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518828739?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:01","pubTimestamp":1741536085,"startTime":"0","endTime":"0","summary":"3月10日，Theriva Biologics, Inc.公布财报，公告显示公司2024财年净利润为-25.65百万美元，同比减少39.78%；其中营业收入为0.00美元，每股基本收益为-19.03美元。从资产负债表来看，Theriva Biologics, Inc.总负债20.67百万美元，其中短期债务600000.00美元，资产负债比为1.93，流动比率为2.15。机构评级：截至2025年3月10日，当前有1家机构对Theriva Biologics, Inc.目标价做出预测，其中目标均价为6.00美元，其中最低目标价为6.00美元，最高目标价为6.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000311a268989e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000311a268989e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165626744","title":"Theriva Biologics 2024财年GAAP每股收益$(19.03)，优于$(24.11)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1165626744","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165626744?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:26","pubTimestamp":1741296399,"startTime":"0","endTime":"0","summary":"Theriva Biologics(TOVX) 2024财年GAAP每股收益$(19.03)，优于$(24.11)的预期。以上内容来自Benzinga Earnings专栏，原文如下：$Theriva Biologics(TOVX)$ FY 2024 GAAP EPS $(19.03) Beats $(24.11) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Theriva Biologics 2024财年GAAP每股收益$(19.03)，优于$(24.11)的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663458","title":"Theriva Biologics, Inc.盘中异动 临近收盘股价大跌5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663458?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:42","pubTimestamp":1741034539,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时42分，Theriva Biologics, Inc.股票出现波动，股价快速跳水5.55%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体跌幅为0.27%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044219abe699d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044219abe699d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516946305","title":"Theriva Biologics, Inc.盘中异动 股价大涨7.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516946305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516946305?lang=zh_cn&edition=full","pubTime":"2025-03-01 03:41","pubTimestamp":1740771693,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日03时41分，Theriva Biologics, Inc.股票出现异动，股价大幅上涨7.14%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，Camp4 Therapeutics Corporation、Enveric Biosciences, Inc.、Bioxcel Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3229.64%、587.33%、386.41%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.90%、48.19%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010341339896bc1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010341339896bc1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514418190","title":"Theriva Biologics, Inc.盘中异动 股价大跌5.92%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514418190","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514418190?lang=zh_cn&edition=full","pubTime":"2025-02-26 04:50","pubTimestamp":1740516650,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日04时50分，Theriva Biologics, Inc.股票出现异动，股价大幅跳水5.92%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.13%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为2125.92%、1184.71%、1025.50%，振幅较大的相关个股有Organovo Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为241.19%、224.55%、127.49%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045050abdcd496&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045050abdcd496&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513214139","title":"Theriva Biologics, Inc.盘中异动 下午盘股价大跌5.28%报1.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513214139","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513214139?lang=zh_cn&edition=full","pubTime":"2025-02-22 04:08","pubTimestamp":1740168505,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日04时08分，Theriva Biologics, Inc.股票出现波动，股价急速下跌5.28%。截至发稿，该股报1.53美元/股，成交量2.1091万股，换手率0.76%，振幅4.04%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040825abd7f3f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040825abd7f3f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512485409","title":"Theriva Biologics, Inc.盘中异动 早盘大幅拉升5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512485409?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:59","pubTimestamp":1739977164,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时59分，Theriva Biologics, Inc.股票出现波动，股价大幅拉升5.73%。截至发稿，该股报1.66美元/股，成交量6020股，换手率0.22%，振幅5.73%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225925988b366f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219225925988b366f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512019639","title":"Theriva Biologics, Inc.盘中异动 下午盘大幅跳水6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512019639","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512019639?lang=zh_cn&edition=full","pubTime":"2025-02-19 03:00","pubTimestamp":1739905249,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日03时00分，Theriva Biologics, Inc.股票出现波动，股价急速下挫6.77%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Aditxt, Inc.、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为810.83%、207.52%、166.94%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219030049a24ae48f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219030049a24ae48f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511444529","title":"Theriva Biologics, Inc.盘中异动 股价大涨9.15%报1.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511444529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511444529?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:58","pubTimestamp":1739458689,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时58分，Theriva Biologics, Inc.股票出现波动，股价大幅拉升9.15%。截至发稿，该股报1.67美元/股，成交量9327股，换手率0.34%，振幅1.28%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213225809a244b1dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213225809a244b1dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TOVX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510337934","title":"Theriva Biologics, Inc.盘中异动 股价大涨5.59%报1.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510337934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510337934?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:04","pubTimestamp":1739293456,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时04分，Theriva Biologics, Inc.股票出现异动，股价快速拉升5.59%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Omega Therapeutics, Inc.、Lipella Pharmaceuticals Inc.、Oramed Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3013.08%、1342.30%、439.48%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、59.46%、58.60%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212010416961f61ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212010416961f61ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509202156","title":"Theriva Biologics, Inc.盘中异动 下午盘快速上涨5.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509202156","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509202156?lang=zh_cn&edition=full","pubTime":"2025-02-07 02:04","pubTimestamp":1738865061,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日02时04分，Theriva Biologics, Inc.股票出现波动，股价大幅拉升5.59%。Theriva Biologics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Lipella Pharmaceuticals Inc.、Geovax Labs Inc C/Wts 29/09/2025、Palatin Technologies, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为6604.00%、1658.12%、167.41%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Palatin Technologies, Inc.，振幅分别为125.58%、64.30%、58.78%。Theriva Biologics, Inc.公司简介：Theriva Biologics Inc是一家临床阶段的制药公司，开发一种新的溶瘤腺病毒平台，以解决未满足需求的毁灭性癌症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207020421961a38f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207020421961a38f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TOVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.therivabio.com","stockEarnings":[{"period":"1week","weight":0.0867},{"period":"1month","weight":-0.0463},{"period":"3month","weight":0.7523},{"period":"6month","weight":0.4128},{"period":"1year","weight":-0.4208},{"period":"ytd","weight":0.4591}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.114},{"period":"6month","weight":0.0821},{"period":"1year","weight":0.2268},{"period":"ytd","weight":0.0819}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Theriva Biologics, Inc.最初成立于1986年10月17日。它是一家多元化的临床阶段公司，于2009年经过一系列合并和更名后在内华达州注册成立。该公司专注于开发治疗癌症和相关疾病的疗法，其主要肿瘤候选药物VCN-01是一种临床阶段的溶瘤腺病毒，设计用于静脉和玻璃体内给药。它还拥有其他胃肠病治疗资产。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.186157},{"month":2,"riseRate":0.5,"avgChangeRate":0.040995},{"month":3,"riseRate":0.25,"avgChangeRate":-0.118127},{"month":4,"riseRate":0.5,"avgChangeRate":0.204751},{"month":5,"riseRate":0.25,"avgChangeRate":-0.286533},{"month":6,"riseRate":0.5,"avgChangeRate":0.101238},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.104421},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.095614},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.250272},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.113385},{"month":11,"riseRate":0.25,"avgChangeRate":0.035119},{"month":12,"riseRate":0.25,"avgChangeRate":-0.164416}],"exchange":"AMEX","name":"Theriva Biologics","nameEN":"Theriva Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Theriva Biologics(TOVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Theriva Biologics(TOVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Theriva Biologics,TOVX,Theriva Biologics股票,Theriva Biologics股票老虎,Theriva Biologics股票老虎国际,Theriva Biologics行情,Theriva Biologics股票行情,Theriva Biologics股价,Theriva Biologics股市,Theriva Biologics股票价格,Theriva Biologics股票交易,Theriva Biologics股票购买,Theriva Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Theriva Biologics(TOVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Theriva Biologics(TOVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}